Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CVS GroupCVSGF 89 EV-to-EBIT is 24.11 as of Jul. 30, 2026, which is 37% below its 10-year median of 38.11. GuruFocus rates CVSGF with a GF Score™ of 89/100 and a GF Value™ of $16.86 (Fairly Valued). The stock has 4 warning signs investors should review. Among 471 Healthcare Providers & Services companies, CVS Group ranks worse than 70.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CVS Group's Enterprise Value for the quarter that ended in Dec. 2025 was $1,501.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CVS Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $62.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Group EV-to-EBIT Related Terms
CVS Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CVS Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, CVS Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CVS Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CVS Group's EV-to-EBIT falls into.
CVS Group's current Enterprise Value is $1,498.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CVS Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $62.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Group (CVSGF) has a EV-to-EBIT of 24.11 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CVS Group and its competitors. This is 37% below median its historical median of 38.11. Over the past decade, CVS Group's EV-to-EBIT has ranged from 12.59 to 104.82. According to the industry distribution chart, CVS Group ranks #331 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 70.3%.
Is CVS Group's EV-to-EBIT too high?
CVS Group's current EV-to-EBIT of 24.11 is 37% below median its 10-year median of 38.11. Over the past 10 years, this metric has ranged from a low of 12.59 to a high of 104.82. The Healthcare Providers & Services industry median EV-to-EBIT is 15.73. CVS Group's value of 24.11 is 53.3% above this industry median. Based on the distribution chart, CVS Group ranks #331 out of 471 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CVS Group has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CVS Group's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CVS Group ranks #331 out of 471 companies for EV-to-EBIT. This places CVS Group in the lower half of its industry. The industry median EV-to-EBIT is 15.73. CVS Group's value of 24.11 is 53.3% above this benchmark. Historically, CVS Group's own EV-to-EBIT has ranged from 12.59 to 104.82 over the past decade. While the company's 10-year median is 38.11 vs. the industry median of 15.73, CVS Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.73, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Group's current EV-to-EBIT of 24.11 is 53.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CVS Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Group's current EV-to-EBIT is 24.11, which is 37% below median its own 10-year median of 38.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Group stock overvalued right now?
Based on GuruFocus' analysis, CVS Group (CVSGF) is currently considered Fairly Valued. The stock's GF Value™ is $16.86, compared to a current price of $16.53 — trading 2% below its estimated fair value. The current EV-to-EBIT is 24.11, which is 37% below median its 10-year median of 38.11 and 53.3% above the Healthcare Providers & Services industry median of 15.73. CVS Group's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CVS Group (CVSGF), the current EV-to-EBIT is 24.11 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Group (CVSGF) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Group stock appears to be undervalued.
The current stock price of $16.53 is trading 2% below its estimated GF Value™ of $16.86.
GuruFocus considers CVS Group to be Fairly Valued.
Key valuation signals for CVSGF:
EV-to-EBIT: 24.11 (37% below median its 10-year median of 38.11)
GF Value™: $16.86 vs. price of $16.53 (2% below fair value)
Industry Position: 53.3% above the Healthcare Providers & Services median (#331 of 471)
No single metric tells the full story. See the CVSGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Group PLC is a veterinary service provider in the United Kingdom. The group operates through three business divisions: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. The veterinary practice segment generates the majority of the revenues. The company facilitates its veterinary services through its diagnostics, laboratory reports, and pet cremation services. It also offers retail pharmacy through Animed Direct. Geographically, it generates the majority of its revenue from the United Kingdom and also operates in Australia.
89GF Score
Get the complete analysis for CVSGF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSGF has been successfully added to your 
